Search results
Results from the WOW.Com Content Network
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]
US emergency use authorization (EUA) when used with etesevimab [30] COVID-19: Bapineuzumab [31] mab: humanized: β-amyloid: Alzheimer's disease: Basiliximab [32] Simulect: mab: chimeric: CD25 (α chain of IL-2 receptor) Y: prevention of organ transplant rejections: Bavituximab [1] mab: chimeric: phosphatidylserine: cancer, viral infections BCD ...
They act by inhibiting gene expression of cytokines including Interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, and TNF-alpha by binding to corticosteroid response elements on DNA. [1] This decrease in cytokine production reduces T cell proliferation. With decreased T cell proliferation there is decreased production of IL-2.
Combination therapy or polytherapy is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression).
76399 Ensembl ENSG00000204671 ENSMUSG00000029437 UniProt Q6EBC2 Q6EAL8 RefSeq (mRNA) NM_001014336 NM_029594 RefSeq (protein) NP_001014358 NP_083870 Location (UCSC) Chr 12: 122.17 – 122.17 Mb Chr 5: 123.62 – 123.63 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Interleukin-31 (IL-31) is a protein that in humans is encoded by the IL31 gene that resides on chromosome 12. IL-31 is ...
Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis.
Currently approved checkpoint inhibitors target the molecules CTLA4, PD-1, and PD-L1. PD-1 is the transmembrane programmed cell death 1 protein (also called PDCD1 and CD279), which interacts with PD-L1 (PD-1 ligand 1, or CD274). PD-L1 on the cell surface binds to PD-1 on an immune cell surface, which inhibits immune cell activity.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file